Abstract：
UNASSIGNED: Graft versus host disease (GVHD) is the common complication seen after allogeneic hematopoietic stem cell transplantation (HSCT) and a pleomorphic syndrome that resembles autoimmune and other immunologic disorders, leading to profound immune dysregulation and organ dysfunction. The most common targets of GVHD are skin, gastrointestinal tract and liver. GVHD is classified as acute graft versus host disease (aGvHD) if it occurs within the first 100 days after HSCT and chronic graft versus host disease(cGVHD) if it occurs after day 100. The skin is most frequently and earliest affected by aGvHD, followed by the gastrointestinal tract and liver. An ideal biomarker would predict the onset and severity of clinical acute GVHD and help to direct management, and this is an area of active research regarding the use of biomarkers for diagnosis and prognosis of acute GVHD. Recently, elafin has been identified as a potential plasma biomarker for aGVHD.
UNASSIGNED: We searched the databases PubMed, Cochrane library, and medRxiv for all studies investigating the Diagnostic or prognostic role of elafin in GVHD. We set the search strategy incorporating the search terms, \'elafin\', \'graft versus host\', and \'GVHD\', and operated using the Boolean operators \'AND\', and \'OR\'. Thus, retrieved articles were then exported on an Excel® sheet, and duplicates were removed. The systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After selecting the study based on inclusion criteria, data on study characteristics and biomarker description was extracted on a pre-determined data extraction table on the Microsoft Excel version. The quality assessment of the included studies was determined using the QUIPS tool.
UNASSIGNED: The search revealed 547 studies and 6 studies that met the eligibility criteria of this review have been included. The major finding of our study is the significant elevation of elafin in skin aGVHD.
UNASSIGNED: Elafin is a significant biomarker for diagnosis and prognosis of skin aGVHD and should be assessed within 2 weeks of the onset of the disease.
UNASSIGNED: We searched the databases PubMed, Cochrane library, and medRxiv for all studies investigating the Diagnostic or prognostic role of elafin in GVHD. We set the search strategy incorporating the search terms, \'elafin\', \'graft versus host\', and \'GVHD\', and operated using the Boolean operators \'AND\', and \'OR\'. Thus, retrieved articles were then exported on an Excel® sheet, and duplicates were removed. The systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After selecting the study based on inclusion criteria, data on study characteristics and biomarker description was extracted on a pre-determined data extraction table on the Microsoft Excel version. The quality assessment of the included studies was determined using the QUIPS tool.
UNASSIGNED: The search revealed 547 studies and 6 studies that met the eligibility criteria of this review have been included. The major finding of our study is the significant elevation of elafin in skin aGVHD.
UNASSIGNED: Elafin is a significant biomarker for diagnosis and prognosis of skin aGVHD and should be assessed within 2 weeks of the onset of the disease.
摘要：
移植物抗宿主病（GVHD）是异基因造血干细胞移植（HSCT）后常见的并发症，是一种类似于自身免疫和其他免疫疾病的多形性综合征，导致严重的免疫失调和器官功能障碍。GVHD最常见的目标是皮肤,胃肠道和肝脏。如果GVHD发生在HSCT后的前100天内,则将其分类为急性移植物抗宿主病(aGvHD),如果其发生在第100天后,则将其分类为慢性移植物抗宿主病(cGVHD)。皮肤最常见和最早受aGvHD影响，其次是胃肠道和肝脏。理想的生物标志物可以预测临床急性GVHD的发作和严重程度，并有助于指导治疗。这是关于使用生物标志物诊断和预后急性GVHD的活跃研究领域。最近,elafin已被确定为aGVHD的潜在血浆生物标志物。
■我们搜索了数据库PubMed,科克伦图书馆,和medRxiv用于所有研究elafin在GVHD中的诊断或预后作用的研究。我们设置了包含搜索词的搜索策略，\'elafin\',\'移植物抗宿主\'，和\'GVHD\',并使用布尔运算符\'AND\'进行操作，和\'或\'。因此，然后将检索到的文章导出到Excel®表上，并删除了重复项。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目进行系统评价。在根据纳入标准选择研究后，在MicrosoftExcel版本的预定数据提取表上提取了有关研究特征和生物标志物描述的数据.使用QUIPS工具确定纳入研究的质量评估。
■搜索显示547项研究和6项符合本审查资格标准的研究已被纳入。我们研究的主要发现是皮肤aGVHD中elafin的显着升高。
■Elafin是皮肤aGVHD诊断和预后的重要生物标志物，应在疾病发作后2周内进行评估。
■我们搜索了数据库PubMed,科克伦图书馆,和medRxiv用于所有研究elafin在GVHD中的诊断或预后作用的研究。我们设置了包含搜索词的搜索策略，\'elafin\',\'移植物抗宿主\'，和\'GVHD\',并使用布尔运算符\'AND\'进行操作，和\'或\'。因此，然后将检索到的文章导出到Excel®表上，并删除了重复项。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目进行系统评价。在根据纳入标准选择研究后，在MicrosoftExcel版本的预定数据提取表上提取了有关研究特征和生物标志物描述的数据.使用QUIPS工具确定纳入研究的质量评估。
■搜索显示547项研究和6项符合本审查资格标准的研究已被纳入。我们研究的主要发现是皮肤aGVHD中elafin的显着升高。
■Elafin是皮肤aGVHD诊断和预后的重要生物标志物，应在疾病发作后2周内进行评估。
